AR102324A1 - Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados - Google Patents

Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados

Info

Publication number
AR102324A1
AR102324A1 ARP150102268A ARP150102268A AR102324A1 AR 102324 A1 AR102324 A1 AR 102324A1 AR P150102268 A ARP150102268 A AR P150102268A AR P150102268 A ARP150102268 A AR P150102268A AR 102324 A1 AR102324 A1 AR 102324A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
residue
polypeptide
acid sequence
Prior art date
Application number
ARP150102268A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR102324A1 publication Critical patent/AR102324A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP150102268A 2014-07-17 2015-07-16 Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados AR102324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14177564 2014-07-17

Publications (1)

Publication Number Publication Date
AR102324A1 true AR102324A1 (es) 2017-02-22

Family

ID=51178812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102268A AR102324A1 (es) 2014-07-17 2015-07-16 Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados

Country Status (18)

Country Link
US (2) US11066450B2 (ko)
EP (1) EP3169357B1 (ko)
JP (1) JP2017522320A (ko)
KR (1) KR20170023191A (ko)
CN (1) CN106795208A (ko)
AR (1) AR102324A1 (ko)
AU (1) AU2015289192A1 (ko)
BE (1) BE1022641B1 (ko)
BR (1) BR112017000521A2 (ko)
CA (1) CA2954745A1 (ko)
EA (1) EA201692552A1 (ko)
ES (1) ES2722773T3 (ko)
IL (1) IL249822A0 (ko)
MX (1) MX2017000776A (ko)
SG (1) SG11201610945PA (ko)
TR (1) TR201901062T4 (ko)
WO (1) WO2016008960A1 (ko)
ZA (1) ZA201700170B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
BR112017000519A2 (pt) * 2014-07-17 2017-11-21 Glaxosmithkline Biologicals Sa "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
EA201692552A1 (ru) 2014-07-17 2017-06-30 Глаксосмитклайн Байолоджикалс С.А. МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
NZ766444A (en) 2014-07-23 2024-01-26 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
US20230137914A1 (en) * 2016-11-25 2023-05-04 Glaxosmithkline Biologicals, S.A. nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2021126421A1 (en) 2019-12-19 2021-06-24 Dow Technology Investments Llc Processes for preparing isoprene and mono-olefins comprising at least six carbon atoms
JP2024507828A (ja) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド B群髄膜炎菌組換えワクチン
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5960055B2 (ja) * 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌fHBPポリペプチド
CA2792683A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
WO2011126863A1 (en) * 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
EA201692552A1 (ru) 2014-07-17 2017-06-30 Глаксосмитклайн Байолоджикалс С.А. МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
BR112017000519A2 (pt) 2014-07-17 2017-11-21 Glaxosmithkline Biologicals Sa "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"

Also Published As

Publication number Publication date
US20220002355A1 (en) 2022-01-06
US20170226161A1 (en) 2017-08-10
ES2722773T3 (es) 2019-08-16
ZA201700170B (en) 2019-06-26
BR112017000521A2 (pt) 2017-11-21
CN106795208A (zh) 2017-05-31
US11066450B2 (en) 2021-07-20
TR201901062T4 (tr) 2019-02-21
JP2017522320A (ja) 2017-08-10
BE1022641A1 (fr) 2016-06-23
BE1022641B1 (fr) 2016-06-23
SG11201610945PA (en) 2017-01-27
CA2954745A1 (en) 2016-01-21
AU2015289192A1 (en) 2017-02-02
WO2016008960A1 (en) 2016-01-21
MX2017000776A (es) 2017-05-04
KR20170023191A (ko) 2017-03-02
EP3169357B1 (en) 2018-11-07
US11939357B2 (en) 2024-03-26
EP3169357A1 (en) 2017-05-24
IL249822A0 (en) 2017-03-30
EA201692552A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
AR102324A1 (es) Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
AR104635A1 (es) COMPOSICIONES A BASE DE LISTERIA INMUNOGÉNICA QUE COMPRENDEN FUSIONES DE ANTÍGENO Y ActA TRUNCADA Y MÉTODOS DE USO DE ESTAS
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
CO2018009120A2 (es) Genes del factor viii optimizados
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MY192481A (en) Factor viii chimeric proteins and uses thereof
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
JP2013172734A5 (ko)
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
SV2017005545A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
WO2016130628A8 (en) Griffithsin mutants
RU2017135038A (ru) Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
PH12018502430A1 (en) Vaccines

Legal Events

Date Code Title Description
FB Suspension of granting procedure